BBC News
Published
image copyrightScience Photo Library
A drug company that increased the price of a crucial thyroid remedy more than 10-fold has prompted fines of more than £100m by the competition watchdog.
Advanz pushed up the price of thyroid tablet packs from £20 in 2009 to £248 in 2017, making the drug unaffordable for the NHS.
It "exploited a loophole enabling it to reap much higher profits", the Competition and Markets Authority said.
The fine applies to Advanz and two private equity firms.
The CMA said its latest fine sent "a clear message" to the pharmaceutical sector that breaking the law would not be tolerated.